| image courtesy of: scientistlive.com |
A Maryland biotechnology firm on Tuesday said research has shown that an experimental anthrax vaccine can remain stable in the stockpile for three years (see GSN, Feb. 24, 2010).
PharmAthene's SparVax recombinant protective antigen vaccine is intended to provide protection against infection by the potential bioterror agent with fewer doses over a shorter timespan than the current treatment.
"Demonstration of 36 month final product stability is considered an important technical milestone under our current contract with the [Health and Human Services Department's] Biomedical Advanced Research and Development Authority (BARDA)," PharmAthene Executive Vice President and Chief Scientific Officer Thomas Fuerst said in a press release. "We are extremely pleased to announce this achievement, which suggests that our rPA product candidate is both highly stable and potent. Stability has historically been a stumbling block for other recombinant anthrax vaccine programs, so we're especially excited about these ongoing results, which represent an important breakthrough for PharmAthene's rPA vaccine program" (PharmAthene release, July 12).
No comments:
Post a Comment